Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mitochondrial protein hyperacetylation in the failing heart
Julie L. Horton, … , Joshua J. Coon, Daniel P. Kelly
Julie L. Horton, … , Joshua J. Coon, Daniel P. Kelly
Published February 25, 2016
Citation Information: JCI Insight. 2016;1(2):e84897. https://doi.org/10.1172/jci.insight.84897.
View: Text | PDF
Research Article Cardiology Metabolism

Mitochondrial protein hyperacetylation in the failing heart

  • Text
  • PDF
Abstract

Myocardial fuel and energy metabolic derangements contribute to the pathogenesis of heart failure. Recent evidence implicates posttranslational mechanisms in the energy metabolic disturbances that contribute to the pathogenesis of heart failure. We hypothesized that accumulation of metabolite intermediates of fuel oxidation pathways drives posttranslational modifications of mitochondrial proteins during the development of heart failure. Myocardial acetylproteomics demonstrated extensive mitochondrial protein lysine hyperacetylation in the early stages of heart failure in well-defined mouse models and the in end-stage failing human heart. To determine the functional impact of increased mitochondrial protein acetylation, we focused on succinate dehydrogenase A (SDHA), a critical component of both the tricarboxylic acid (TCA) cycle and respiratory complex II. An acetyl-mimetic mutation targeting an SDHA lysine residue shown to be hyperacetylated in the failing human heart reduced catalytic function and reduced complex II–driven respiration. These results identify alterations in mitochondrial acetyl-CoA homeostasis as a potential driver of the development of energy metabolic derangements that contribute to heart failure.

Authors

Julie L. Horton, Ola J. Martin, Ling Lai, Nicholas M. Riley, Alicia L. Richards, Rick B. Vega, Teresa C. Leone, David J. Pagliarini, Deborah M. Muoio, Kenneth C. Bedi Jr., Kenneth B. Margulies, Joshua J. Coon, Daniel P. Kelly

×

Figure 3

Hyperacetylated mitochondrial proteins in failing human heart are involved in multiple energy transduction pathways.

Options: View larger image (or click on image) Download as PowerPoint
Hyperacetylated mitochondrial proteins in failing human heart are involv...
Lysine-acetylated proteins (indicated by circles, protein symbols are noted) identified by mass spectrometry in dilated cardiomyopathy (DCM) patients and nonfailing (NF) control samples (n = 5/group) in each of the 3 main mitochondrial fuel oxidation/ATP synthesis pathways (β-oxidation, tricarboxylic acid [TCA] cycle, and electron transport complex [ETC]) are shown. All acetylated residues with at least ± 1.5 fold change for mean DCM/NF values are shown. Mean DCM acetylation levels that were significantly different compared to NF control values based on Student’s t test are also indicated (*P < 0.05). Specific lysine acetylation sites are noted in parentheses. Acetylation status is indicated by color coding: proteins with increased acetylation (DCM/NF) are in red; proteins with decreased acetylation are in blue; and proteins with no significant change are in gray. All acetylation levels were normalized to corresponding protein abundance. SDHA, succinate dehydrogenase A.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts